Phenelzine (sulfate)

Phenelzine sulfate, an antidepressant agent, is an irreversible and orally active  monoamine oxidase (MAO-A and MAO-B)   inhibitor. Phenelzine sulfate inhibits  GABA transaminase  and  primary amine oxidase (PrAO), and sequester reactive aldehydes. Phenelzine sulfate also inhibits  LSD1  (Ki: 5.6 μM) and suppresses oxidative stress and lipogenesis. Phenelzine sulfate elevates neurotransmitters (serotonin, norepinephrine, dopamine) . Phenelzine sulfate is studied in neurological, metabolic and cancer diseases for depression and anxiety disorders, stroke, spinal cord injury, traumatic brain injury, multiple sclerosis, Parkinson’s disease, Alzheimer’s disease, inflammatory pain, obesity and prostate cancer[1][2][3][4].

Product Specifications

CAS Number

[156-51-4]

UNSPSC

12352005

Hazard Statement

H301

Target

GABA Receptor; Histone Demethylase; Monoamine Oxidase

Type

Reference compound

Related Pathways

Epigenetics; Membrane Transporter/Ion Channel; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Cancer; Metabolic Disease; Inflammation/Immunology; Neurological Disease; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/Phenelzine-sulfate.html

Concentration

10mM

Purity

99.96

Solubility

DMSO : ≥ 100 mg/mL

Smiles

NNCCC1=CC=CC=C1.O=S(O)(O)=O

Molecular Formula

C8H14N2O4S

Molecular Weight

234.27

Precautions

H301

References & Citations

[1]Matveychuk D, et al. Overview of the Neuroprotective Effects of the MAO-Inhibiting Antidepressant Phenelzine. Cell Mol Neurobiol. 2022;42 (1) :225-242.|[2]Bustin KA, et al. Phenelzine-based probes reveal Secernin-3 is involved in thermal nociception. Mol Cell Neurosci. 2023;125:103842.|[3]Prusevich P, et al. A selective phenelzine analogue inhibitor of histone demethylase LSD1. ACS Chem Biol. 2014;9 (6) :1284-1293.|[4]Carpéné C, et al. Body fat reduction without cardiovascular changes in mice after oral treatment with the MAO inhibitor phenelzine. Br J Pharmacol. 2018;175 (12) :2428-2440.|[5]Musgrave T, et al. The MAO inhibitor phenelzine improves functional outcomes in mice with experimental autoimmune encephalomyelitis (EAE) . Brain Behav Immun. 2011 Nov;25 (8) :1677-88.